Clinical Trials Browser

INDUSTRY × ceritinib × Gastrointestinal × Clear all

NCT02638909 2018-04-02

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Phase 2 Terminated

Gastrointestinal

Adenocarcinoma Of Esophagus, Cholangiocarcinoma